1 results match your criteria: "University of Utah and GEWVAMC.[Affiliation]"
Atrial Fibrillation and Bleeding in Patients With Chronic Lymphocytic Leukemia Treated with Ibrutinib in the Veterans Health Administration.
Fed Pract
May 2020
is a Senior Research Analyst at the University of Utah School of Medicine and the George E. Wahlen Veterans Affairs Medical Center (GEWVAMC) in Salt Lake City, Utah; is a Senior Research Analyst at the University of Utah School of Medicine and GEWVAMC; is a Research Associate at GEWVAMC; is a Medical Writer at the University of Utah School of Medicine and GEWVAM; is an Associate Professor at the University of Utah School of Medicine and GEWVAMC; is an Assistant Professor of Medicine at the Huntsman Cancer Institute, University of Utah and GEWVAMC.
Background: Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in adults. The introduction of novel oral agents, starting with ibrutinib in 2013, has revolutionized the therapeutic landscape; however, clinical trials have suggested an association between ibrutinib and the risk of bleeding-related adverse events and atrial fibrillation (Afib) in patients with CLL.
Methods: Patients diagnosed and treated for CLL at the Veterans Health Administration (VHA) from 2010 to 2014 were followed until December 31, 2016, death, or lack of utilization of hematology/oncology services for ≥ 18 months; or until incidence of another cancer.